Cooperative Agreement UG3DA062919
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$818K
Federal Agency
National Institute on Drug Abuse
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
Connecticut, USA
Similar Awards
This Cooperative Agreement award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop and validate a novel patient-reported outcome measure of substance-related consequences for use in substance use disorder (SUD) treatment trials. The $352,064 award, effective from August 1, 2025 to July 31, 2027, will be executed by the Mclean Hospital Corporation, a non-profit psychiatric teaching hospital affiliated with...
The National Institute on Drug Abuse (NIDA) awarded a $1,076,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Dynamicare Health Inc. in Wareham, MA. The award will fund a Phase II randomized clinical trial to evaluate the efficacy of DCH-003, a digital therapeutic that delivers contingency management for the treatment of stimulant use disorder. The trial will compare standard clinic care plus DCH-003 to standard care plus a sham digital app, with the...
This $671,310 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of novel therapeutic agents for the treatment of Stimulant Use Disorder (STUD). The awardee, Verisim Life, Inc., is leveraging its proprietary AI-driven drug discovery platform, BioiSim, to expedite the development of STUD drug candidates with favorable pharmacokinetic, pharmacodynamic, and safety profiles. The key goals of...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $304,215 to Carina Medical LLC to develop and validate a novel software platform for decentralized clinical trials (DCTs) in substance use disorder (SUD). The project aims to leverage large language models (LLMs) to automate data collection and improve efficiency and accuracy for SUD DCTs. Key objectives include developing the software...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $400,000 to Mountainpass Technology LLC to develop, refine, and evaluate a customized version of their "MyTrials" integrated remote biomarker capture system for decentralized clinical trials (DCTs) focused on substance use disorders (SUDs). The project aims to address key methodological limitations of DCTs for SUDs by creating a product...
This Project Grant award of $688,271, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a research project at Yale University to examine spatial and temporal variability in a state's illicit drug market. The key activities under this award include: 1) Expanding street-based testing of drug samples from individuals who use drugs, 2) Developing a wastewater sampling and testing system to determine community-level drug...
This federal Cooperative Agreement award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop and validate a Clinical Outcomes Assessment (COA) for opioid withdrawal management. The $702,974 award, effective June 15, 2025 through May 31, 2027, will support the Research Foundation of the City University of New York (RFCUNY) in an iterative process to expand upon existing withdrawal scales, integrate insights...
The National Institute on Drug Abuse (NIDA) awarded a $306,528 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Addinex Technologies, Inc. The grant will fund the development of a medication adherence and monitoring system to support decentralized clinical trials for substance use disorder (SUD). The project aims to adapt Addinex's existing medication management system to provide researchers running SUD clinical trials with a tool for at-home dispensing that...
The federal Cooperative Agreement award, funded by the National Institute on Drug Abuse (NIDA) under CFDA Program 93.279 - Drug Use and Addiction Research Programs, provides $2,983,510 to The Leland Stanford Junior University to assess the efficacy of deep transcranial magnetic stimulation (DTMS) in modulating neural circuits associated with methamphetamine use disorder (MUD) and reducing relapse risk. The project consists of two phases. In the initial UG3 phase, the researchers will enroll 30...
This $3,226,170 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) will support a randomized clinical trial to evaluate the effectiveness of cognitive skills training interventions in improving outcomes for offenders with substance use disorders. The award recipient, Lovelace Biomedical Research Institute, will conduct the study to demonstrate the reliability and generalizability of their prior pilot findings, which showed...